Ventyx Biosciences outlined its 2025 pipeline strategy, emphasizing its NLRP3 inhibitor portfolio, VTX2735 and VTX3232. The company announced that the first subjects have been dosed in a Phase 2 trial of VTX3232 for participants with obesity and cardiometabolic risk factors. Topline data from this trial is expected in the second half of 2025.
The Phase 2 trial of VTX2735 in participants with recurrent pericarditis is expected to initiate in January 2025, with topline data also anticipated in the second half of 2025. Furthermore, topline data from the ongoing Phase 2 biomarker trial of VTX3232 in patients with early Parkinson’s disease is expected in the first half of 2025.
Ventyx also provided an update on its financial position, reporting an unaudited cash, cash equivalents, and marketable securities balance of $252.9 million as of December 31, 2024. This balance is expected to fund planned operations into at least the second half of 2026, supporting the advancement of its clinical programs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.